Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
>>> Cannabis banking legislation moves forward in US Senate
Reuters
September 27, 2023
By Arunima Kumar and Sourasis Bose
https://news.yahoo.com/us-senate-committee-votes-advance-145335619.html
(Reuters) -A U.S. Senate committee on Wednesday voted to advance a marijuana banking bill, raising hopes for the cash-dependent cannabis sector to get access to regular banking services.
The Secure and Fair Enforcement Regulation Banking Act (SAFER) bill, introduced by a bipartisan group of senators last week, will now move to the Senate floor.
Most banks in the country do not service cannabis companies as marijuana remains illegal at the federal level despite several states legalizing its medicinal and recreational use.
The new bill seeks to ensure that all businesses — including state-sanctioned cannabis businesses — will have access to deposit accounts, insurance and other financial services.
Shares of SNDL, Trulieve Cannabis, Cronos Group rose between 1% and 3% following the vote.
U.S. cannabis-related ETF AdvisorShares Pure US Cannabis ETF gained 1.4%.
"We are hopeful that the revised language and clearer guidelines for financial institutions will continue to break through the many unproductive hurdles that have prolonged the passage of this bill for far too long," said cannabis firm Acreage Holdings.
An earlier version of the bill, the SAFE Banking Act, had failed to secure a Senate vote despite the House of Representatives passing it seven times.
"Realizing this first vote out of the Senate signals strong bipartisan support from both chambers of Congress," said Trulieve CEO Kim Rivers.
Last month, the U.S. Department of Health and Human Services (HHS) recommended easing restrictions on marijuana. The agency suggested classifying the substance to a Schedule III drug from Schedule I.
The recommendation was provided to the Drug Enforcement Agency, which has the final authority on rescheduling.
<<<
---
>>> Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive
January 23, 2023·
https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-023348419.html
Key Takeaways; Cannabis Sector
22nd Century announced partnerships with Core-Mark and Eby-Brown, two of the largest U.S. convenience store distributors.
Scotts Miracle-Gro announced timing for Q1 financial results and conference call.
Tilray’s revenue declines as net losses increase; if cannabis sales continue to be slow, the company may switch to fruit and beer sales.
Key Takeaways; Psychedelic Sector
Cybin announced positive findings from sponsored Kernel Flow® feasibility study measuring the brain’s response to psychedelics.
Awakn’s Project Kestrel fueling the company’s growth.
Cannabis stocks have started 2023 very strongly with the cannabis stock index up 9.0% year to year, which is well ahead of the 3.5% increase in the S&P 500. This week’s news will be dominated by earnings reports as several industry titans from a range of sectors are expected to release their financial results.
Below is a review of the companies that dominated the news in the cannabis and psychedelic industries during the past week, along with a preview of the upcoming week.
Top Marijuana Companies for Week
#1: 22nd Century
The largest distributors of convenience stores in the United States, Core-Mark International and Eby-Brown Company, both signed new distribution agreements with 22nd Century Group, Inc. (NASDAQ: XXII), which is a leading biotechnology company that’s committed to improve health through reduced nicotine tobacco use and cutting-edge plant technologies in hemp/cannabis and hops.
As part of the new collaboration agreement, the store distributors will assist in nationwide distribution of VLN®. According to a press statement from 22nd Century Group, the company’s VLN® solutions are now available for purchase by qualified Core-Mark and Eby-Brown clients as a part of the state and regional rollout program of 22nd Century Group.
In addition, 22nd Century stated that they will participate in 11 regional trade fairs in 2023 that are sponsored by the distributors, giving the company the chance to meet thousands of Core-Mark and Eby-independent Brown’s retail and chain store operators.
John Miller, president of tobacco products for 22nd Century Group, commented on this significant development: “22nd Century’s new partnership agreements with two of the largest, most respected convenience store distributors in the United States make possible the launch of VLN® cigarettes in virtually every key U.S. market we are targeting in our state-by-state, region-by-region roll-out strategy.”
#2: ScottsMiracle-Gro
The Scotts Miracle-Gro Company (NYSE: SMG), the top marketer of branded consumer products for indoor and hydroponic growth as well as lawn and garden, stated that its first quarter financial results will be released on February 1, 2023, ahead of the opening of the U.S. stock market. The Company then announced that they would hold a conference call to go through those results at 9:00 a.m. ET.
The stock of Scotts Miracle-Gro has increased by almost 25% since the beginning of the year, making it one of the best performers in the cannabis industry this year. The stock experienced a significant rally on Friday, rising by more than 7%.
With Scotts Miracle-Gro now expected to report earnings for the first quarter of 2023 on February 1, 2023. Analysts are expecting the company to report earnings of $4.4 per share, up from $4.09 per share reported in the same quarter of 2020. The company has seen solid revenue growth over the last few quarters and is expected to continue this trend in the first quarter. Analysts are forecasting revenue to increase 8.7% year-over-year to $2.3 billion.
With the anticipated legalization of cannabis in several states and the expanding acceptance of medical marijuana, the company is expected to benefit from increased demand for outdoor and gardening products. This should help drive higher sales and earnings for the company in 2023.
#3: Tilray
Tilray Brands, Inc. (NASDAQ: TLRY) released financial results for the second fiscal quarter that concluded on November 30, 2022. Sales decreased 7% from $155 million in 2021 to $144 million in 2022. In addition, revenue decreased from the $153 million it was in the prior quarter. On the positive note, the company did manage to generate $25.4 million in free cash flow and $29.2 million in operating cash flow during the quarter.
Furthermore, according to Tilray CEO, Irwin Simon, if cannabis sales continue to decline, the company may increase its footprint in the alcoholic beverage market or start cultivating fruits and vegetables to make up for a shortfall in the cannabis sales.
Top Psychedelic Companies for Week
#1: Cybin
Biopharmaceutical company Cybin Inc. (NYSE: CYBN), which focuses on advancing psychedelics to therapeutics, released key findings from a feasibility study that was recently completed by its partner HI, LLC dba Kernel. The study examined Kernel’s Flow® wearable technology to assess the psychedelic effects of ketamine on cerebral cortex hemodynamics. According to the company, the findings of this company-sponsored study will help determine the program’s future pathway.
Cybin, a Canadian biotechnology company, has seen a return of 233.9% in January 2023, strongly outperforming the S&P and other major composite index. The company’s strong performance in January was driven by strong news flow related to its Phase 1 clinical trials of its lead drug candidate CYB003. The company announced positive results from the study, showing that the drug was well tolerated and had a positive effect on reducing symptoms of depression.
The results of the clinical trial have added to the excitement surrounding the company’s drug pipeline and have further solidified the company as one of the leaders in the psychedelic drug space. This positive sentiment has sent the stock soaring as investors have been piling into the stock in expectation of continued success from the company.
#2: Awakn
Awakn Life Sciences Corp. (NEO: AWKN) (OTC: AWKNF) is a Canadian biotechnology company focused on the development of psychedelic therapeutics, mainly focusing on Ketamine-Assisted Psychotherapy for Alcohol Use Disorder. Awakn experienced a successful year in 2022 thanks to substantial accomplishments in the psychedelic sector.
The company’s strong performance has been driven by Project Kestrel, which is the company’s lead clinical development program. Phase II a/b KARE clinical study of its lead drug candidate results showed that the drug was well tolerated and had a positive effect on the treatment of Alcohol Use Disorder.
Overall, Awakn has had a remarkable run and investors are optimistic about the company’s future prospects. With Phase II clinical trial in the bag, investors are now looking ahead to the Phase III study, which is funded by UK Government agencies. If the results from the Phase 3 trials are equally positive, then the stock could continue to rise.
<<<
---
>>> Scotts Miracle-Gro posts narrower-than-expected net loss and beats revenue mark
MarketWatch
Feb. 1, 2023
By Steve Gelsi
https://www.marketwatch.com/story/scotts-miracle-gro-posts-narrower-than-expected-net-loss-and-beats-revenue-mark-01675254093?siteid=yhoof2
Scotts Miracle-Gro. Co. SMG, said Wednesday its first-quarter loss widened to $64.7 million, or $1.17 a share, from a loss of $50 million, or 90 cents a share in the year-ago quarter.
The lawn and cannabis growing products company’s adjusted loss widened to $1.02 a share from 88 cents a share in the year-ago period. Revenue fell 7% to $526.6 million. Analysts expected Scotts Miracle-Gro to lose $1.34 a share on revenue of $502.4 million, according to estimates compiled by FactSet.
Scotts Miracle-Gro said it’s targeting $185 million in annualized savings for an initiative called project springboard. The company also reported record December shipments in its U.S. Consumer business that “contributed to a strong early season buildout demonstrating confidence in the lawn and garden season.”
First-quarter sales in its Hawthorne cannabis growing product unit fell 31% to $131.5 million, compared with $190.6 million, due to “challenges” in the industry, the company said.
Looking ahead, Scotts Miracle-Gro is projecting 20% to 30% lower sales for Hawthorne in fiscal 2023. Shares of Scotts Miracle-Gro are up 48.6% in 2023, compared to a 10.7% rise by the Nasdaq.
<<<
---
Hemp, Inc. $HEMP focuses on the provision of industrial hemp. Its products include the King of Hemp pre-roll blends, fortified pre-rolls; Bubba Kush hemp; caviar/moon rocks; and diamonds and crumbles. The company also involved in processing and farming industrial hemp; extracting hemp CBD oil; and educating and empowering hemp farmers and entrepreneurs with knowledge, processing, infrastructure, and support. In addition, it engages in the sale of hemp accessories, such as extractors, harvesters, storage bags, containers, fertilizer, soil amendments, humidifiers, dehumidifiers, balers, greenhouses, and greenhouse equipment; and drying, trimming, curing, storing, and brokering for other farmers harvesting hemp, as well as provision of research and development, hemp consulting, and educational entertainment services. The company was formerly known as Marijuana, Inc. and changed its name to Hemp, Inc. in June 2012. Hemp, Inc. was incorporated in 2008 and is based in Las Vegas, Nevada.
I love this. Many years ago when I “tried” to grow my own cannabis outdoors, Miracle-Grow was a go-to. Maybe that’s why I was a failure. LOL
>>> Scotts Miracle-Gro still believes in cannabis' future. Here's how it plans to be a part of it.
The Etain marijuana dispensary in Manhattan. Riv Capital, backed with debt financing from a Scotts Miracle-Gro subsidiary, acquired Etain this year. New York state is expanding to adult recreational use from medical marijuana; sales could start by year's end.
By Carrie Ghose
Columbus Business First
Nov 11, 2022
https://www.bizjournals.com/columbus/news/2022/11/10/scotts-miracle-gro-cannabis-future-hathorne-riv.html?utm_source=sy&utm_medium=nsyp&utm_campaign=yh
Scotts Miracle-Gro Co. took a bruising from this year’s tumult in the U.S. marijuana industry, but the company is investing even more in a shot at eventual part ownership of a major consumer cannabis brand when federal prohibition ends.
The Marysville lawn and garden company has invested $175 million via convertible notes in Riv Capital Inc., and has an option to lend more. With a handful of former Scotts executives in top leadership, the Canadian firm is in the process of acquiring a cannabis company in New York, where recreational use is about to begin.
“We looked at the future of the industry,” Scotts CEO Jim Hagedorn told Columbus Business First. “Branded consumable products is where the money is going to be.”
Scotts (NYSE: SMG) supplies marijuana growers and indoor agriculture through its Hawthorne Gardening Co. subsidiary, which it built through $1.4 billion in acquisitions over the past eight years.
It’s the difference between owning a hops farm or Anheuser-Busch, said Chris Hagedorn, Scotts executive vice president and Hawthorne’s president.
Riv, based in Toronto, was formerly an investment arm of Canopy Growth Corp., separated in a divestiture last year.
The debt financing structure through a subsidiary keeps Scotts at legal arms’ length while cannabis remains federally outlawed, but the notes can convert to shares once the ban lifts – a maximum 49% stake depending on how much more it lends. Scotts also names four of seven board seats, including Chris Hagedorn.
“I think we’re the first ones to structure it the way we did,” Chris Hagedorn said in the joint interview with his father.
“We don’t control the business,” he said. “We have been able to seed some of the management team with former Scotts people.”
Mark Sims, also a Riv director, joined as CEO in March after almost 15 years at Scotts, most recently as senior vice president for strategy and mergers and acquisitions.
Other leaders that migrated from Scotts: COO Mike Totzke moved over in June after 17 years, most recently as a Hawthorne team lead, and is in charge of growing the New York business. Frank Tice, legal director, had been on the legal team advising Hawthorne. Amanda Rico, a Scotts vice president of human resources, joined Riv as HR chief last month.
Sims’ appointment marked a major strategy shift: Instead of a venture capital investor in Canadian cannabis growers and suppliers, Riv is getting directly into the business of growing and selling cannabis in the United States.
Riv achieved its goal of early entry into a high-population state where the market is about to grow quickly, Chris Hagedorn said. The company has closed the first phase of a $247 million cash-and-stock acquisition of Etain LLC and Etain IP LLC, which operate the full spectrum from cultivation to dispensaries in New York. It started in medical marijuana and will expand with recreational use.
Riv also is building a new 75,000-square-foot cultivation facility in Buffalo – with supplies and design consulting from Hawthorne.
Publicly traded tobacco companies have made similar moves, but most large consumer-facing companies have stayed out of the industry.
Optimism for Riv follows a rough year for Hawthorne. Oversupply in state marijuana markets, especially California, caused growers to pull back and Hawthorne sales to drop by half to $716 million. The division with an 11.5% operating margin last year had a full-year operating loss of $21 million in fiscal 2022.
Hawthorne cut hundreds of jobs, is closing distribution centers to consolidate with Scotts facilities and is shutting down product lines, including a lighting brand it acquired in December.
Accounting write-offs on several acquisitions led Scotts to its first annual net loss since 2008, and overall company sales dropped by $1 billion from a record 2021 to $3.9 billion.
A patchwork of state regulations and onerous tax structures have plagued the cannabis industry. Jim Hagedorn on investor calls has taken responsibility for misjudging how slowly a Democratic president and Congress would move on ending federal cannabis prohibition.
As part of cost-cutting this year, Scotts Miracle-Gro sold and leased back its Hawthorne subsidiary’s headquarters in Vancouver, Washington.
Industry advocates are hoping at least the Safe Banking Act can pass in a lame duck session, allowing state licensed operators to access banking and creating momentum for more profound reforms.
“I hope Sen. (Chuck) Schumer (the Senate majority leader) is good for his word when he says we’re close,” Chris Hagedorn said.
Scotts first invested in Riv in August 2021 through a subsidiary. Analysts have complained about the investment, Chris Hagedorn said.
“It’s not going to make money yet,” he said. “That business is on track. I’m extremely excited about the prospects of that business.”
And he is equally confident of the future for the original Hawthorne business, because of the future of the marijuana business.
“There’s no use case question here. Will Americans adopt cannabis usage? They did that a long time ago,” Chris Hagedorn said. “There is a healthy, profitable business to be had. Changes are necessary, and we are making them now.”
<<<
---
Great news for $EDXC! Endexx Corp. has secured a new $3.8 million USD order for its newly acquired, non-nicotine-based vape product, HYLA from customers in Italy.
This $3.8M order is significant in two ways for Endexx. First, it provides the Company with more than $6M of revenue in its first two fiscal quarters of 2023, significantly surpassing its revenue for the entirety of the previous fiscal year. Given that the order came from customers in Italy, it is expected that this influential market will also expand the Company’s footprint in regions to the east, where it is believed that in addition to providing a geographic connection, Italy is considered very influential from both an economic and cultural perspective.
https://finance.yahoo.com/news/endexx-secures-3-8m-order-120000642.html
>>> Analysts see no lift for downbeat cannabis stocks from Chuck Schumer’s bill
MarketWatch
July 22, 2022
By Steve Gelsi
https://www.marketwatch.com/story/analysts-see-no-lift-for-downbeat-cannabis-stocks-from-chuck-schumer-bill-11658497851?siteid=yhoof2
Stifel analyst W. Andrew Carter sees a negative bias continuing toward most cannabis stocks.
An ambitious and long-awaited cannabis bill from Senate Majority Leader Chuck Schumer is unlikely to pass and will not likely stoke interest in U.S. cannabis stocks, analysts say.
While the formal introduction of the Cannabis Administration and Opportunity Act (CAOA) this week has drawn some praise, it landed with a thud on Wall Street.
The AdvisorShares Pure US Cannabis ETF MSOS fell about 2% on Thursday, the day Schumer unveiled the bill. It’s down 53.2% in 2022, compared to a drop of about 24% by the Nasdaq. The index was up 0.5% in early trades on Friday.
“We continue to outline a negative bias to public cannabis equities,” Stifel analyst W. Andrew Carter said Friday in a research note.
He reiterated a buy rating on WM Technology MAPS and hold ratings on GrowGeneration Corp. GRWG, Hydrofarm Holdings HYFM, and Scotts Miracle-Gro SMG, as beneficiaries of the current environment.
“We believe this legislation has no prospects of success with modest reforms still possible during this Congress, but extremely unlikely,” Carter said. “We believe many of the initiatives included here not only [impede] Republican support, but the aggressiveness hampers bipartisan attention for effective evaluation potentially impacting the prospects for more modest reforms.”
Jefferies analyst Owen Bennett said the CAOA reflects growing momentum behind cannabis reform and its introduction now should give Congress more time to switch to a more “passable” measure by the end of the year.
Instead of the wide-ranging CAOA, pundits see better prospects for the SAFE Banking measure to help open up financial services to cannabis companies as a narrower proposal that’s already passed the House of Representatives seven times in various forms.
“With the CAOA now introduced, the Senate can move onto bills such as the SAFE, which have bipartisan support and a better chance of passing, in our view,” said Aaron Grey, an analyst at Alliance Global Partners.
On July 14, the House passed the National Defense Authorization Act with the SAFE Banking measure attached to it. A Senate version of the bill would only need 50 votes as opposed to the 60 required for a standalone measure, Grey said.
Meanwhile, industry players and special interest groups mostly welcomed the CAOA.
Vince Ning, CEO and co-founder of California-based cannabis wholesaler Nabis LLC, said industry players “are always excited to see federal legislation to legalize cannabis move forward.”
He described Schumer’s CAOA as the most comprehensive piece of legislation that has been filed.
“Even if parts of the CAOA do not pass, we know this will at least bring important pieces of the legislation to light again, such as wider banking access and support for financial services,” Ning said. “The industry has been starved for cheaper and more conventional sources of capital, particularly for small businesses in a bear market economy both in cannabis and globally. “
Voicing criticism of the measure, Kevin Sabet, co-founder and president of Smart Approaches to Marijuana, said the CAOA “marches forward on unchecked marijuana legalization, despite the challenges plaguing states with legal weed.” He said the measure also ignores potential harm from high-potency marijuana now available.
<<<
---
$EDXC - Endexx Corporation emphasizes becoming a competitive player in the premium Men’s Skincare and Grooming category. With the expansion into select Target stores nationwide, Endexx is now in over 8000 Mass Retail stores in the US. $EDXC is now in four of the top eight retailers in the USA.
https://www.globenewswire.com/news-release/2022/07/19/2481808/0/en/Endexx-s-New-Blesswell-Skincare-Line-Introduced-in-Select-Target-Stores-Nationwide.html
>>> Why Shares of Scotts Miracle-Gro Fell 16.5% in June
Motley Fool
By Scott Levine
Jul 6, 2022
https://www.fool.com/investing/2022/07/06/why-shares-of-scotts-miracle-gro-fell-165-in-june/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
KEY POINTS
Management reduced 2022 sales and adjusted EPS guidance.
Numerous analysts cut their price targets and downgraded the stock.
The grass doesn't seem like it will be as green in 2022 as the company once thought.
What happened
Failing to flourish in the first five months of 2022, shares of Scotts Miracle-Gro (SMG 0.85%), the lawn care and pest control purveyor, had fallen more than 41%. And the downward trend didn't stop in June. According to data from S&P Global Market Intelligence, Scotts Miracle-Gro's stock plunged 16.5% last month, nearly doubling the S&P 500's decline of 8.4%.
In addition to the company's downward revision of its 2022 guidance, a flood of bearish commentary on the stock from Wall Street drowned investors' hopes for the stock.
So what
On June 8, management revealed its new -- more dour -- expectations for 2022, which included lower expectations on both the top and bottom lines. Initially, the company had forecast overall sales growth of flat to 3% 2022 compared to 2021. While management expected U.S. sales to be flat or decline 3%, it believed that Hawthorne, the cannabis-related subsidiary, would drive year-over-year growth about 8% to 12%. With regard to profitability, management had originally forecast 2022 adjusted earnings per share of $8.50 to $8.90.
Growth, however, doesn't seem to be in the cards for 2022. Management now estimates U.S. sales will shrink 4% to 6%, and Hawthorne sales will plummet 40% to 45% due to an oversupply of cannabis in the market. Furthermore, management slashed adjusted EPS guidance, estimating that the company will now report adjusted EPS of $4.50 to $5.
Shortly after the company issued its revised forecast, analysts responded with their own pessimism:
Truist cut its price target to $85 from $185, downgrading the stock to hold from buy.
J.P. Morgan slashed its price target to $95 from $130, downgrading the stock to neutral from overweight.
Raymond James trimmed its price target to $110 from $125.
Stifel lowered its price target to $93 from $116, maintaining a hold rating.
Especially notable action came from Chris Carey, an analyst with Wells Fargo, where the bearish fervor grew like a weed last month. On June 2 (prior to management's announcement of lowered guidance), Carey reduced the price target on Scotts Miracle-Gro to $130 from $145. Carey slashed the price target again on June 9 and June 22, when he reduced the price targets to $115 and $85, respectively.
Now what
For an industry stalwart like Scotts Miracle-Gro, the sell-off last month seems a little overblown. While 2022 may not be as lush as management originally foresaw, this leader in lawn and garden supplies should hardly be dismissed altogether. Management largely attributes the predicted lower sales in 2022 to an oversupply of inventory -- a challenge for sure, but not an irreparable harm to the company's long-term prospects.
<<<
---
>>> Scotts Miracle-Gro Down 10% On Profit Warning
ETF.com
by Ben Kissam
June 8, 2022
https://finance.yahoo.com/news/scotts-miracle-gro-down-10-184500486.html
Scotts Miracle-Gro Company Class A (SMG) dropped 10% on Wednesday after releasing revised numbers for 2022 revenue and adjusted earnings.
The company now estimates an adjusted earnings per share between $4.50 and $5.00, significantly lower than its initial 2022 prediction of $8.00, which it called "likely unattainable." Retail orders for the company came in $300 million lower than estimates for May 2022.
In total, 119 ETFs hold SMG shares. The Cambria Cannabis ETF (TOKE) has the largest SMG exposure, at 9.11%. In fact, the top three ETFs are all heavily invested in the cannabis industry.
All together, 5.5 million shares of SMG are held in ETFs. At the top of the list is the iShares Core S&P Mid-Cap ETF (IJH), which has 1.16 million shares, or roughly 21% of this total. The stock seems to sit near the division between the small cap and midcap segments.
Scotts Miracle-Gro is held by 37 vanilla, cap-weighted ETFs, accounting for about 31% of all funds. It is by far the largest category of ETFs holding SMG
Old Company, New Business
Founded in 1868, Scotts Miracle-Gro has been a staple of the American agriculture industry, selling seed, lawn and pest control products for more than 150 years.
Since 2014, though, the company has become a big name in cannabis. It started with the formation of Hawthorne, its hydroponic growing subsidiary, which, at the time, was one of the first big investments by a major U.S. corporation into the cannabis industry.
Outspoken about its belief that cannabis legalization is a matter of "when," not "if," the company has made moves in the past few years to both expedite the federal legalization and position itself to eventually sell cannabis directly to consumers.
To this point, its early investments in cannabis have paid off. In 2021, Hawthorne accounted for nearly 30% of Scotts' total sales. This division of the company has also seen a growth of 5% in each of the last three years.
2022 doesn't look like it will be a banner year for Hawthorne, though. CEO Jim Hagedorn said it expects a 4-6% decrease in U.S. consumer sales overall, and as much as a 40% drop in Hawthorne sales for its year ending on September 30, 2022.
<<<
---
A step in the right direction
https://www.benefits.va.gov/homeloans/documents/docs/marijuana-derived_income_VA_loan.pdf
>>> These are the new rules for investors who want to buy marijuana stocks
MarketWatch
April 30, 2022
By Michael Brush
https://www.marketwatch.com/story/these-are-the-new-rules-for-investors-who-want-to-buy-marijuana-stocks-11651168408?mod=MW_article_top_stories
The cannabis sector has had a big drawdown. The crash has several lessons for investors.
If technology stocks are causing you pain, just be thankful you don’t own cannabis shares.
Exchange traded funds including ETFMG Alternative Harvest MJ, -1.86%, AdvisorShares Pure Cannabis YOLO, +0.92% and the simply named Cannabis THCX, -1.62% are at all-time lows.
You can’t say the same about the Nasdaq Composite Index COMP, -1.40%.
Rather than gloat — or cry because you own them — it’s always better to learn from market train wrecks. In this spirit, I rounded up seven key investing rules for everyone — cannabis bulls or not — from the marijuana meltdown.
Let’s jump in.
Rule #1: Don’t make the government your investment partner
This is a rule I have followed for years. Avoid any companies where a big part of the investment thesis depends on government action. There’s a simple reason: Governments are run by politicians, who are often irrational. That makes them unpredictable.
Obviously, there are exceptions. Biotechnology, pharma and energy companies routinely count on government approvals. But it’s possible to find companies in these sectors where only a small portion of overall growth depends on government action.
That’s not the case with cannabis stocks, whose future depends almost completely on legalization, tax reform and permission for companies to use banks.
Cannabis investors got burned by ignoring this rule in early 2021 when the outlook for cannabis seemed bright because Democrats took control of Washington, D.C.
That’s why cannabis stocks went to parabolic highs in February 2021, says Tim Seymour, portfolio manager of the Amplify Seymour Cannabis ETF CNBS, -0.11%. “Everybody thought cannabis was going to be legal, bankable and taxable.”
It’s a bad move to put so much trust in politicians. If you bought the AdvisorShares Pure US Cannabis ETF MSOS, +5.42% on these hopes in February 2021 at $50 to $55, you are now down over 60% vs gains of 16% for the S&P 500 SPX, -0.57%.
Rule #2: If the government is your partner, expect it to take its sweet time
“The biggest mistake I made when I got into this industry was expecting federal regulation to change quickly,” says Emily Flippen, a cannabis analyst at The Motley Fool.
“Congress never moves that quickly, especially on something as big as prohibition,” says Mike Goral, who runs the national cannabis and hemp practice at the accounting and consulting firm Armanino LLP.
And now, an all-encompassing cannabis-reform bill from Democratic Sen. Chuck Schumer of New York looks overly ambitious because it tries to do too much at once, says Goral. Incremental change is more realistic, starting with much-needed banking reform, says Goral. “We have clients that have to carry duffle bags of cash to pay their taxes. This is not safe.”
Jason Wilson, who follows the cannabis sector at the ETF firm ETFMG, also expects gradual progress in stages on banking reform, decriminalization and tax-law reform that allows cannabis companies to deduct expenses.
Rule #3: Avoid commodity products
A good, basic rule of investing is to own companies that have pricing power because they do something unique. That’s not the case with companies selling agricultural commodities such as corn, wheat and marijuana.
“What’s the sustainable competitive advantage of any of these companies?” asks Todd Lowenstein, the equity strategist with The Private Bank at Union Bank.
He’s avoided the group because cannabis is a commodity product with “negligible differentiation devoid of pricing power. For these to work, you’d have to count on a first-mover advantage to gain scale, cost and distribution efficiencies, and establish branding to build awareness, which is expensive.”
That is happening for some companies to some degree, meaning those approved to sell in limited-license states like New Jersey, says Seymour.
“Companies in New Jersey will print money for a few years,” he says. After that, wholesale prices will fall, as they have in states west of the Mississippi where cannabis has been legal for longer.
Publicly traded cannabis sellers face the additional challenge of a thriving illicit market, where prices can be far lower since legal sellers pay high taxes. Around 70% of cannabis sales in California are in the illicit market, says Goral.
The pushback to my “avoid commodities” rule from passionate cannabis investors is that Starbucks SBUX, -1.24%, for example, sells a commodity, coffee, and it has been a fabulous investment. Which brings me to my next rule.
Rule #4: It’s hard to pick the “Starbucks of cannabis”
“While there are craft beers and fine wines of cannabis, it’s tough to figure out who will command this consumer attention in the long run,” says Goral, at Armanino. I think he’s right about this. How many people knew back in the 1990s that Starbucks would be the success that it is? I sure didn’t.
And if marijuana becomes fully legal, won’t an expert brand marketer such as Altria MO, +1.11% or even Starbucks wind up being the “Starbucks of cannabis”? After all, they have a lot of expertise in brand development and probably more than cannabis companies taking a stab at it now, such as Tilray TLRY, -3.07%, Curaleaf CURLF, +8.22%, Green Thumb Industries GTBIF, +9.87% and Canopy Growth CGC, -1.65%.
Rule #5: Be aware of media hype
Most investors, including me, have made the following mistake early on: You buy a stock because you hear about it on CNBC or some other financial media — only to watch it fade over time. Oops, you just got caught up in the media hype with a little bit of FOMO mixed in.
“If you are hearing about something in the financial media, it is probably the worst time to invest in it because it is probably in a cycle of hype,” says Flippen.
This pattern has played out regularly in the cannabis space whenever there was incremental progress on legislation in Washington, D.C. You can avoid this by ignoring what’s in the headlines and focusing on fundamentals, and by following the next rule.
Rule #6: Be diversified
To diversify, start by owning a mix of the best pureplay operators with high-quality cash flow, says Flippen. In her view, this means Green Thumb Industries and Cresco Labs CRLBF, +5.02%. But she says you also must look beyond the growers to ancillary companies that don’t touch the plant. This is a variation on the old “picks and shovels” theme from the dot-com era.
In that regard, she cites Innovative Industrial Properties IIPR, -4.70%, a real estate investment trust offering buildings used in the industry; Scotts Miracle-Gro SMG, -4.49% ; and Constellation Brands STZ, -1.76%, which has an investment in Canopy.
Note the top holdings of the Cambria Cannabis ETF TOKE, -0.44% are mostly companies that don’t grow, but have some connection to the cannabis industry. They include: Scotts Miracle-Gro, Constellation Brands, Innovative Industrial Properties, Jazz Pharmaceuticals JAZZ, -0.38%, British American Tobacco BTI, -0.27%, Altria, Philip Morris International PM, -0.83%, Turning Point Brands TPB, -2.18% and Imperial Brands IMBBY, -1.05%.
Rule #7: Have a long-term horizon
After Prohibition ended in the U.S. in 1933, alcohol stocks returned 20% per year in the next decade, nearly double the returns of the overall market, says Meb Faber, chief investment officer of Cambria Investment Management, which runs the TOKE ETF. “There’s a similar situation developing around the globe as legal restrictions on cannabis production and consumption are being lifted.”
But this decade-long timeline of performance tells me you can wait for politicians to actually act on legalization, banking and tax law reform, before getting exposure to the cannabis space.
<<<
-
Endexx Corp - EDXC had a movement a few days ago. It may move again as a result of its expanding product range, which is generating more income than ever before. Marijuana is also fast becoming legal. EDXC is ideally positioned to leverage this.
https://pubcoinsight.com/2022/04/05/the-more-act-passes-the-house-floor-vote%ef%bf%bc%ef%bf%bc-2/
$CWBHF $TVOG $CBDD — The House passed legislation Friday that would legalize marijuana nationwide, eliminating criminal penalties for anyone who manufactures, distributes or possesses the substance. https://www.nbcnews.com/politics/congress/house-vote-bill-legalize-marijuana-rcna22527
>>> Pennsylvania Senate Approves Marijuana Banking Bill, Sending It To The House
Marijuana Moment
April 13, 2022
By Kyle Jaeger
https://www.marijuanamoment.net/pennsylvania-senate-approves-marijuana-banking-bill-sending-it-to-the-house/
The Pennsylvania Senate on Wednesday approved a bill to safeguard banks and insurers against being penalized by state regulators for working with state-legal medical marijuana businesses.
The bipartisan legislation from Sens. John DiSanto (R) and Sharif Street (D) moved through two committees in recent days before being taken up on the floor and passing in a 46-3 vote. It now heads to the House.
This effort is yet another example of how states are working to provide financial protections to institutions that are willing to service the cannabis market as Congress continues to stall on a federal fix.
“Federal prohibition has forced the cannabis industry to deal with cash, as proceeds may be considered a federal crime,” DiSanto said on the floor on Wednesday, adding that the cash-intensive nature of the existing marketplace “makes dispensaries a target for armed robbery.”
“Improved access to financial services will reduce this public safety risk,” he said. “Banking this cash in Pennsylvania will grow our economy and lower costs for medical patients.”
The Pennsylvania bill would not immunize banks and insurers from potential federal repercussions—but it’s an interim step meant to signal to the financial sector that they at least won’t face penalties under state law.
DiSanto and Street previously circulated a co-sponsorship memo to colleagues ahead of the banking bill’s introduction that addressed the public safety problems posed to marijuana businesses without access to traditional financial services, forcing many to operate with large volumes of cash that make them targets of crime.
Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Street said on the floor on Wednesday that the legislation will “take the first step” toward reform by “allowing and making it more feasible for people in the cannabis business to move away from being a cash business [and] to use our banking system.”
The move to provide state-level protections could add pressure on congressional lawmakers to enact a federal change, such as the bipartisan Secure and Fair Enforcement (SAFE) Banking Act that has passed the House in some form six times at this point, only to stall in the Senate.
One possible vehicle for that congressional policy change could be a large-scale manufacturing and innovation bill, where marijuana banking was included by the House and may now be taken up by appointed negotiators in both chambers as they head to conference.
The text of the Pennsylvania legislation states that a “financial institution authorized to engage in business in this Commonwealth may provide financial services to or for the benefit of a legitimate cannabis-related business and the business associates of a legitimate cannabis-related business.” The same protections would also be codified for insurers.
However, it specifies that the bill would not require banks or insurers to provide services to medical marijuana businesses.
The legislation says that state government agencies cannot “prohibit, penalize or otherwise discourage a financial institution or insurer from providing financial or insurance services to a legitimate cannabis-related business or the business associates of a legitimate cannabis-related business.”
It also says agencies cannot “recommend, incentivize or encourage a financial institution or insurer” to not provide services just because a business is associated with marijuana.
Further, state agencies could “not take adverse or corrective supervisory action on a loan made to a legitimate cannabis-related business,” the text says.
These are the types of policies that advocates and stakeholders have been pushing Congress to enact at the federal level, but it remains to be seen when that might happen.
Rodney Hood, a board member and former chairman of the National Credit Union Administration (NCUA), has repeatedly emphasized the urgent need for a federal resolution to the marijuana banking problem. He recently applauded efforts by lawmakers in states like Pennsylvania to address the issue within their jurisdictions, but he said it’s not enough.
The federal financial regulator also noted that New York lawmakers are seeking to provide tax breaks for the forthcoming marijuana market, sending a budget proposal to the governor over the weekend that would do just that.
A New York senator is also seeking to give banks in the state a little peace of mind about working with legal marijuana businesses, filing a bill on Tuesday that would allow regulators to disclose certain information about cannabis licensees to financial institutions.
Washington State Treasurer Mike Pellicciotti (D) has also been especially vocal about the need for congressional reform, and he wrote in a recent letter to his colleagues in other states that it’s “just not safe to have this financial volume in cash.”
Pellicciotti made similar remarks at a recent conference of the National Association of State Treasurers (NAST). And Colorado Treasurer Dave Young echoed that sentiment in a recent interview with Marijuana Moment.
The sponsor of the congressional SAFE Banking Act, Rep. Ed Perlmutter (D-CO), told Marijuana Moment on Monday that he’s hopeful that his reform legislation will be attached to the final America COMPETES Act that’s heading to conference.
The congressman pointed out that “more than two-thirds of the conferees [for the large-scale bill] have already voted for or cosponsored the SAFE Banking Act.”
One of those conferees, longstanding marijuana reform champion Rep. Earl Blumenauer (D-OR), said in an op-ed for Marijuana Moment this week that the banking reform measure as “a huge step” toward public safety and equity in the industry.
Perlmutter also recently spoke with Treasury Secretary Janet Yellen about the marijuana banking issue during a hearing of the House Financial Services Committee. And the secretary said that it’s “extremely frustrating” that Congress hasn’t “been able to resolve it.”
The sponsor has even made a point to talk about enacting the reform legislation during committee hearings on ostensibly unrelated or wider-ranging legislation, like at a recent House Rules Committee hearing.
At a recent event hosted by the American Bankers Association (ABA), the congressman said that he will “continue to be a real pest, and persistent in getting this done” before he retires from Congress at the end of the session.
Despite recently saying that he’s “confident” that the Senate will take up his bill this session, Perlmutter recognized that while he’s supportive of revisions related to criminal justice reform, taxation, research and other issues, he knows that “as we expand this thing, then we start losing votes, particularly Republican votes and we got enough votes in the Senate to do it” as is.
Ahead of last month’s ABA event, the financial group released a poll that it commissioned showing that a strong majority of Americans support freeing up banks to work with marijuana businesses without facing federal penalties.
Meanwhile, the number of banks that report working with marijuana businesses ticked up again near the end of 2021, according to recently released federal data.
It’s not clear if the increase is related to congressional moves to pass a bipartisan cannabis banking reform bill, but the figures from the Financial Crimes Enforcement Network (FinCEN) signal that financial institutions continue to feel more comfortable servicing businesses in state-legal markets.
Some Republicans are scratching their heads about how Democrats have so far failed to pass the modest banking reform with majorities in both chambers and control of the White House, too. For example, Rep. Rand Paul (R-KY) criticized his Democratic colleagues over the issue in December.
Meanwhile in Pennsylvania, another Republican senator recently announced that he will soon be introducing a bill to allow medical marijuana patients in the state to buy cannabis edibles at dispensaries.
Sen. Dan Laughlin (R), who has also sponsored legislation to legalize marijuana for adult use and allow patients to cultivate cannabis for personal use, said that patients “should be able to buy edible medical cannabis that is safe, uniform and securely packaged and labeled, just as they do in 25 other states that have legalized medical cannabis.”
Separately, the Senate Law and Justice Committee held the last of three scheduled hearings on marijuana legalization last month, taking testimony that’s designed to help inform a forthcoming reform bill that the panel’s chairman is actively drafting.
Sen. Mike Regan (R), who chairs the panel, circulated a cosponsorship memo last year along with Rep. Amen Brown (D) to build support for the reform, and these meetings are designed to give lawmakers added context into the best approach to legalization for the state.
While reform bills have been introduced in past sessions and the policy change has the support of Gov. Tom Wolf (D), the series of hearings marked the first times a legislative panel had debated recreational legalization in the Republican-controlled Pennsylvania General Assembly.
Pennsylvania lawmakers could also take up more modest marijuana reform proposals like a bill filed late last year to expand the number of medical marijuana cultivators in the state, prioritizing small farms to break up what she characterized as a monopoly or large corporations that’s created supply problems.
Additionally, another pair of state lawmakers—Reps. Jake Wheatley (D) and Dan Frankel (D)—formally unveiled a legalization bill they’re proposing last year.
Philadelphia voters also approved a referendum on marijuana legalization in November that adds a section to the city charter saying that “the citizens of Philadelphia call upon the Pennsylvania General Assembly and the Governor to pass legislation that will decriminalize, regulate, and tax the use, and sale to adults aged 21 years or older, of cannabis for non-medical purposes.”
Wolf, the governor, said last year that marijuana legalization was a priority as he negotiated the annual budget with lawmakers. However, his formal spending request didn’t contain legislative language to actually accomplish the cannabis policy change.
The governor, who signed a medical cannabis expansion bill in June, has repeatedly called for legalization and pressured the Republican-controlled legislature to pursue the reform since coming out in favor of the policy in 2019. Shortly after he did that, a lawmaker filed a separate bill to legalize marijuana through a state-run model.
Meanwhile, Lt. Gov. John Fetterman (D), who is running for U.S. Senate this year, said one of his key goals in his final year in office is to ensure that as many eligible people as possible submit applications to have the courts remove their cannabis records and restore opportunities to things like housing, student financial aid and employment through an expedited petition program.
A survey from Franklin & Marshall College released last year found that 60 percent of Pennsylvania voters back adult-use legalization. That’s the highest level of support for the issue since the firm started polling people about it in 2006.
An attempt to provide protections for Pennsylvania medical marijuana patients from being charged with driving under the influence was derailed in the legislature last year, apparently due to pushback by the state police association.
Also, a bill meant to promote research into the therapeutic potential of psilocybin mushrooms for certain mental health conditions may be in jeopardy, with the sponsor saying recently that the chair of a key House committee is expressing reservations even after the legislation was amended in an effort to build support.
<<<